Examination of utility in patients of unresectable or recurrent gastric cancer treated with paclitaxel or nab-paclitaxel or paclitaxel+ ramucirumab in our hospital

Takayuki Kii(Osaka Medical and Pharmaceutical University), Kazuhide Higuchi(Osaka University of Pharmaceutical Sciences), Ken Asaishi(Osaka Medical and Pharmaceutical University), Tomohiro Yamaguchi(Japanese Foundation For Cancer Research), Toru Ikegami(Jikei University School of Medicine), Tetsuji Terazawa(Osaka Medical and Pharmaceutical University), M Aoki(Osaka Medical and Pharmaceutical University)
Annals of Oncology
November 1, 2017
Cited by 1


Related Papers